A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : TKI

Search Conditions:
Search Keyword : TKI
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: TKI
Appearance Frequency: 2511 time(s)
Long forms: 31

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
tyrosine kinase inhibitor
(2447 times)
Neoplasms
(1306 times)
EGFR (704 times)
NSCLC (579 times)
CML (543 times)
1995 EGF and TPA stimulate de novo synthesis of PGHS-1 and PGHS-2 through different signal transduction pathways.
tyrosine kinase
(14 times)
Neoplasms
(6 times)
CML (3 times)
EGFR (3 times)
BK (2 times)
2002 [Transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor induces an angiogenic phenotype in human cultured coronary endothelial cells].
TK inhibitor
(13 times)
Neoplasms
(3 times)
TK (12 times)
CML (4 times)
EGFR (3 times)
2000 Effect of tyrosine kinase inhibition on sepsis-induced vascular hyporesponsiveness, inos mrna expression and NF-kappaB nuclear translocation in rats.
Thomas-Kilmann Conflict Mode Instrument
(3 times)
Nursing
(1 time)
DUTCH (1 time)
HBSL (1 time)
2007 Conflict management styles in the health professions.
trypsin-kallikrein inhibitor
(3 times)
Biochemistry
(2 times)
CTI (1 time)
IgG (1 time)
1979 Effect of modification of reactive lysine on antitryptic and antichymotryptic activity of proteinase inhibitor from cow colostrum.
EGFR-TKI
(2 times)
Radiotherapy
(1 time)
NSCLC (2 times)
BMs (1 time)
ctDNA (1 time)
2016 Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.
EGFR-tyrosine kinase
(2 times)
Neoplasms
(2 times)
allo-SCT (1 time)
CML (1 time)
NSCLC (1 time)
2011 Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.
receptor-tyrosine kinase inhibitor
(2 times)
Medicine
(1 time)
EGFR (1 time)
mRCC (1 time)
NSCLC (1 time)
2012 Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
topological Kondo insulator
(2 times)
Natural Science Disciplines
(1 time)
AFTI (1 time)
nAFI (1 time)
TI (1 time)
2013 Surface hall effect and nonlocal transport in SmB₆: evidence for surface conduction.
10  tyrosine-kinase receptor inhibitor
(2 times)
Drug Resistance
(1 time)
AMLs (1 time)
BCLC (1 time)
CML (1 time)
2009 Mechanisms of resistance to FLT3 inhibitors.
11  ABL-TK inhibitors
(1 time)
Medicine
(1 time)
Ph (1 time)
TK (1 time)
2013 Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
12  BCR-ABL-tyrosine kinase inhibitors
(1 time)
Allergy and Immunology
(1 time)
HBV (1 time)
2018 Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
13  first multi-kinase inhibitor
(1 time)
Pharmacology
(1 time)
DTC (1 time)
HCC (1 time)
RCC (1 time)
2015 The adverse effects of sorafenib in patients with advanced cancers.
14  KGFR-selective kinase inhibitors
(1 time)
Neoplasms
(1 time)
KGF (1 time)
KGFR (1 time)
2015 Oncolytic potential of a novel KGFR tyrosine kinase inhibitor using a KGFR-selective breast cancer xenograft model.
15  mortality.Tyrosine kinase inhibitors
(1 time)
Diabetes Mellitus
(1 time)
ACTH (1 time)
MTC (1 time)
2017 ACTH-secreting medullary thyroid cancer: a case series.
16  tamarind Kunitz inhibitor
(1 time)
Biochemistry
(1 time)
FXa (1 time)
STI (1 time)
2012 Structural basis for dual inhibitory role of tamarind Kunitz inhibitor (TKI) against factor Xa and trypsin.
17  third-generation epidermal growth factor receptor (EGFR)tyrosine kinase inhibitor
(1 time)
Drug Therapy
(1 time)
EGFR (1 time)
2018 Safety of osimertinib in EGFR-mutated non-small cell lung cancer.
18  Thomas-Kilmann Conflict Mode Inventory
(1 time)
Psychology
(1 time)
--- 2007 Actual and ideal conflict styles and job distress in a health care organization.
19  Thomas-Kilmann Mode Instrument
(1 time)
Nursing
(1 time)
--- 2001 A gender perspective on conflict management strategies of nurses.
20  Thomas-Kilmann Mode of Conflict Instrument
(1 time)
Education, Medical, Graduate
(1 time)
GME (1 time)
2011 Conflict styles in a cohort of graduate medical education administrators, residents, and board-certified physicians.
21  thoracic kyphosis index
(1 time)
FHP (1 time)
FSP (1 time)
LSST (1 time)
2017 POSTURAL ALTERATIONS IN PATIENTS WITH SUBACROMIAL IMPINGEMENT SYNDROME.
22  thymidine kinase I
(1 time)
Neoplasms
(1 time)
--- 2001 Thymidine kinase 1 immunoassay: a potential marker for breast cancer.
23  tissue kallikrein
(1 time)
Toxicology
(1 time)
--- 2015 Angiotensin processing activities in the venom of Thalassophryne nattereri.
24  tooth-knuckle injury
(1 time)
Wounds and Injuries
(1 time)
PIPJ (1 time)
2016 Predicting serious complications and high cost of treatment of tooth-knuckle injuries: a systematic literature review.
25  topological KI
(1 time)
Medicine
(1 time)
KI (1 time)
2017 Excitons in topological Kondo insulators: Theory of thermodynamic and transport anomalies in SmB_{6}.
26  total knowledge index
(1 time)
Neurology
(1 time)
--- 2018 Knowledge, Attitudes and Concussion Information Sources Among First Nations in Ontario.
27  Trasylol-like inhibitors from bovine lung
(1 time)
Biochemistry
(1 time)
--- 1979 Inhibition of porcine glandular kallikreins by structurally homologous proteinase inhibitors of the Kunitz (Trasylol) type. Significance of the basic nature of amino acid residues in subside positions for kallikrein inhibition.
28  traumatic kidney injury
(1 time)
Histology
(1 time)
AKI (1 time)
FA (1 time)
IL (1 time)
2016 MRL/MpJ mice show unique pathological features after experimental kidney injury.
29  Turkish Coal Enterprises
(1 time)
Traumatology
(1 time)
--- 2017 Analyses of non-fatal accidents in an opencast mine by logistic regression model - a case study.
30  type-I receptor kinase inhibitor
(1 time)
Pharmacology
(1 time)
LZM (1 time)
TGF-beta (1 time)
UUO (1 time)
2008 Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis.
31  tyrosine kinase BCR-ABL inhibitors
(1 time)
Neoplasms
(1 time)
CML (1 time)
2017 Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors.